세계의 프레가발린 시장 : 투약 형태, 약제 클래스별, 용도, 최종 사용자, 유통 채널 예측(2025-2030년)

The Pregabalin Market was valued at USD 1.12 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 7.74%, to USD 1.89 billion by 2030.

Pregabalin, a medication primarily used to treat nerve pain, seizures, and generalized anxiety disorder, represents a significant segment of the global pharmaceutical market due to its broad therapeutic applications. The necessity for pregabalin arises from its efficacy in managing conditions associated with neuropathic pain, fibromyalgia, and epilepsy, creating a robust demand in the healthcare sector. End-use scope primarily includes hospitals, clinics, and homecare settings, tapping into the increasing incidence of such conditions worldwide. Key influencing factors bolstering the pregabalin market include the rising prevalence of chronic pain disorders, expanding geriatric population susceptible to nerve damage, and increasing awareness and diagnosis of neuropathic pain. Moreover, ongoing research and development are aimed at expanding therapeutic indications and improving drug efficacy, presenting new growth opportunities. Recent potential opportunities include formulating pregabalin alternatives with fewer side effects and modifying current dosages to enhance safety and efficacy. To maximize these opportunities, manufacturers could focus on innovative drug delivery systems and generic versions to tap into untapped markets. However, these growth prospects are tempered by challenges such as stringent regulatory frameworks, potential misuse leading to dependency concerns, and the high cost of medication, impacting patient access. Fierce competition from alternative therapies and the expiration of patents further pose market threats. Nonetheless, areas for potential innovation and research are emerging in developing nanotechnology-based formulations and exploring combinations with other drugs to enhance therapeutic outcomes. Additionally, market players could pursue value-based pricing strategies to enhance accessibility without compromising profitability. The nature of the pregabalin market is highly competitive yet poised for growth, with a need for strategic collaborations and continued investment in R&D to address existing limitations and capitalize on new market prospects efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pregabalin Market

The Pregabalin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cases of epilepsy and anxiety disorders
  • Favorable government initiatives for raising awareness for anxiety issues
  • Rising geriartic population with neuropathic pain
• Market Restraints
  • Presence of substitutes and lack of awareness
• Market Opportunities
  • Rising approvals of generic versions of the medicine
  • Advancements and product enhancements for pregabalin
• Market Challenges
  • Adverse effects on health and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Pregabalin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pregabalin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pregabalin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pregabalin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pregabalin Market

A detailed market share analysis in the Pregabalin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pregabalin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pregabalin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pregabalin Market

A strategic analysis of the Pregabalin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pregabalin Market, highlighting leading vendors and their innovative profiles. These include Almelo Private Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, BAL Pharma Ltd., Cipla Limited, Dongbang FTL, Genesis Biotec Inc., Hikal Ltd., Lupin Limited, Medley Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Pregabalin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Dosage Forms, market is studied across Extended Release, Oral Capsule, Oral Solution, and Oral Tablet.
• Based on Drug Class, market is studied across Anticonvulsants and Fibromyalgia Agents.
• Based on Application, market is studied across Anxiety Disorder, Epilepsy, and Neuropathic Pain.
• Based on End-Users, market is studied across Homecare, Hospitals, Research institute, and Specialty Clinics.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cases of epilepsy and anxiety disorders
    • 5.1.1.2. Favorable government initiatives for raising awareness for anxiety issues
    • 5.1.1.3. Rising geriartic population with neuropathic pain
  • 5.1.2. Restraints
    • 5.1.2.1. Presence of substitutes and lack of awareness
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising approvals of generic versions of the medicine
    • 5.1.3.2. Advancements and product enhancements for pregabalin
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects on health and product recalls
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pregabalin Market, by Dosage Forms

• 6.1. Introduction
• 6.2. Extended Release
• 6.3. Oral Capsule
• 6.4. Oral Solution
• 6.5. Oral Tablet

7. Pregabalin Market, by Drug Class

• 7.1. Introduction
• 7.2. Anticonvulsants
• 7.3. Fibromyalgia Agents

8. Pregabalin Market, by Application

• 8.1. Introduction
• 8.2. Anxiety Disorder
• 8.3. Epilepsy
• 8.4. Neuropathic Pain

9. Pregabalin Market, by End-Users

• 9.1. Introduction
• 9.2. Homecare
• 9.3. Hospitals
• 9.4. Research institute
• 9.5. Specialty Clinics

10. Pregabalin Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
• 10.4. Retail Pharmacy

11. Americas Pregabalin Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Pregabalin Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Pregabalin Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Almelo Private Limited
• 2. Amneal Pharmaceuticals LLC
• 3. Aurobindo Pharma Limited
• 4. BAL Pharma Ltd.
• 5. Cipla Limited
• 6. Dongbang FTL
• 7. Genesis Biotec Inc.
• 8. Hikal Ltd.
• 9. Lupin Limited
• 10. Medley Pharmaceuticals Limited
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. Teva Pharmaceutical Industries Ltd.
• 14. Torrent Pharmaceuticals Ltd.
• 15. Zydus Lifesciences Limited